Entry Point Capital, LLC Janux Therapeutics, Inc. Put Options Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
Put Options
0 transactions
Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
---|
Others Institutions Holding JANX
# of Institutions
159Shares Held
37.3MCall Options Held
70.4KPut Options Held
101K-
Ra Capital Management, L.P. Boston, MA9.17MShares$497 Million5.79% of portfolio
-
Orbimed Advisors LLC San Diego, CA2.98MShares$162 Million3.01% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$127 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.33MShares$126 Million0.19% of portfolio
-
Janus Henderson Group PLC London, X01.8MShares$97.7 Million0.04% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $2.26B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...